The announcement of a class action lawsuit against Edwards Lifesciences is likely to negatively impact its stock price in the short term as it raises concerns about potential financial liabilities and reputational damage. The deadline for lead plaintiffs is December 13, 2024, which may keep the issue in the public eye and maintain pressure on the stock.